AIRNA Raises $155M to Advance RNA Editing Therapy for Genetic Lung and Liver Disease

Cambridge, MA and Tubingen, Germany, April 6, 2025 (Business Wire) -- AIRNA secured $155 million in an oversubscribed Series B to advance its RNA-editing therapy for alpha-1 antitrypsin deficiency into clinical trials. The round was led by Venrock and included a strong mix of new and returning investors. The funding supports AIRNA’s broader ambition to develop a pipeline of transformative RNA-editing medicines.

Read full article here.